Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on January 20, 2023. The report details the effective implementation of a 1-for-60 reverse stock split of the Company's common stock, which became effective at 5:00 p.m. Eastern Standard Time on January 20, 2023. The action was taken to meet the continued listing standards of the NYSE American and avoid potential delisting due to low share price.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capitalization changes.
Material Changes
- Reverse Stock Split: A 1-for-60 reverse stock split was executed. No fractional shares were issued; shareholders entitled to fractional shares received one whole share instead.
- Authorized Shares: Reduced from 250,000,000 to 4,166,666 shares.
- Outstanding Shares: Reduced from 117,662,247 (pre-split) to approximately 1,961,037 shares (post-split).
- Trading Details: Shares began trading on a split-adjusted basis on January 23, 2023, under the symbol "OGEN" with a new CUSIP Number (684023 500).
- Derivatives: Stock options and warrants were adjusted proportionately, resulting in a decrease in the number of shares issuable and an increase in exercise prices.
Guidance, Outlook, and Risks
The primary driver for this action was the risk of automatic delisting from the NYSE American due to the trading price of the common stock falling below the exchange's minimum requirements. The filing states that shareholder approval was not required under Florida law as the split proportionally reduced authorized and outstanding shares without adversely affecting rights or paying cash for fractional shares. The filing does not provide specific forward-looking financial guidance or management commentary on operational outlook.
Investor Verification Checklist
- Verify the new CUSIP Number (684023 500) for trading and settlement purposes.
- Confirm the adjusted number of shares held in brokerage accounts reflects the 1-for-60 ratio.
- Review the adjusted exercise prices and share counts for any outstanding stock options or warrants.
- Check the NYSE American listing status to confirm compliance with minimum bid price requirements post-split.